Centogene AG is teaming up with Sarepta Therapeutics Inc., of Cambridge, Mass., to identify patients with Duchenne muscular dystrophy (DMD) in the Middle East and North Africa region. As part of the collaboration, Rostock, Germany-based Centogene will perform complete molecular diagnostic testing, as well as provide diagnostic services to physicians treating patients exhibiting symptoms related to DMD.